InflaRx (IFRX) Net Cash Flow (2016 - 2026)
InflaRx's (IFRX) quarterly Net Cash Flow came in at $237.3 million in Q2 2026, up 743.98% year-over-year from $28.1 million in Q2 2025, and up 366.94% quarter-over-quarter from -$88.9 million in Q1 2026.
Analysis
InflaRx (IFRX) Net Cash Flow (2016 - 2026) Analysis & Trends
InflaRx has disclosed Net Cash Flow across 11 years of filings, most recently posting $237.3 million for Q2 2026.
- In Q2 2026, Net Cash Flow rose 743.98% year-over-year to $237.3 million; the TTM figure through Jun 2026 stood at $152.1 million (down 22.88% YoY), while the FY2025 annual figure was $1.4 million, down 68.86% from the prior year.
- Net Cash Flow came in at $237.3 million for Q2 2026 at InflaRx, up from -$88.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $299.8 million in Q4 2024 to a low of -$125.5 million in Q2 2022.
- Average Net Cash Flow over 5 years is $6.6 million, with a median of -$11.2 million recorded in 2023.
- Year-over-year, Net Cash Flow slumped 19478.78% in 2022 and soared 3521.77% in 2024.
- Over 5 years, Net Cash Flow stood at $277.1 million in 2022, then plunged by 103.16% to -$8.8 million in 2023, then soared by 3521.77% to $299.8 million in 2024, then tumbled by 96.25% to $11.3 million in 2025, then surged by 2009.35% to $237.3 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were $237.3 million in Q2 2026, -$88.9 million in Q1 2026, and $11.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -170.75 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 237.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 237.34 Mn |
| Mar 31, 2026 | -88.91 Mn |
| Dec 31, 2025 | 11.25 Mn |
| Sep 30, 2025 | -7.62 Mn |
| Jun 30, 2025 | -36.86 Mn |
| Mar 31, 2025 | 32.24 Mn |
| Dec 31, 2024 | 299.84 Mn |
| Sep 30, 2024 | -98.05 Mn |
| Jun 30, 2024 | -122.21 Mn |
| Mar 31, 2024 | -79.99 Mn |
| Dec 31, 2023 | -8.76 Mn |
| Sep 30, 2023 | 2.20 Mn |
| Jun 30, 2023 | -13.61 Mn |
| Mar 31, 2023 | 17.28 Mn |
| Dec 31, 2022 | 277.12 Mn |
| Sep 30, 2022 | -89.99 Mn |
| Jun 30, 2022 | -125.52 Mn |
| Mar 31, 2022 | -86.63 Mn |
| Dec 31, 2021 | -51.97 Mn |
| Sep 30, 2021 | -459,611.90 |